文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

在成年β-YAC小鼠中通过离体和在体造血干细胞基因组编辑重新激活γ-珠蛋白

Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
PubMed 文献 · Blood · 2018-05-22

研究以人β-珠蛋白位点转基因(β-YAC)小鼠为模型,用表达CRISPR/Cas9的辅助依赖型人CD46靶向腺病毒载体(HDAd-HBG-CRISPR)破坏γ-珠蛋白启动子内的抑制因子结合区。离体和在体转导造血干/祖细胞后均实现有效靶位点破坏,红细胞中人β-向γ-珠蛋白表达发生明显转换,且经二次移植后维持;长期随访未检测到血液学异常。

要点

  • HDAd-HBG-CRISPR可破坏γ-珠蛋白启动子抑制因子结合区。
  • 离体与在体转导均实现人β-向γ-珠蛋白表达明显转换。
  • 长期随访未检测到血液学异常,为首次在体HSPC CRISPR/Cas9编辑。

核心结论

  • 在β-YAC小鼠离体和在体HSPC转导模型中,HBG启动子编辑实现有效靶位点破坏并使人β-向γ-珠蛋白表达明显转换,长期随访未检测到血液学异常。
  • 这是首次展示通过CRISPR/Cas9成功进行在体HSPC基因组编辑的研究。

研究设计与样本

  • 研究使用人β-珠蛋白位点转基因(β-YAC)小鼠及β-YAC/human CD46-transgenic小鼠。
  • 离体模型:转导β-YAC/human CD46-transgenic小鼠的HSPC后移植入受照射受体。
  • 在体模型:对β-YAC/CD46-transgenic小鼠进行HSPC动员并静脉注射HDAd-HBG-CRISPR。

主要发现

  • 两种模型均显示有效靶位点破坏,成年小鼠红细胞中人β-向γ-珠蛋白表达发生明显转换。
  • 该转换在HSPC二次移植后维持。
  • 长期随访研究中未检测到血液学异常。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Disorders involving β-globin gene mutations, primarily β-thalassemia and sickle cell disease, represent a major target for hematopoietic stem/progenitor cell (HSPC) gene therapy. This includes CRISPR/Cas9-mediated genome editing approaches in adult CD34+ cells aimed toward the reactivation of fetal γ-globin expression in red blood cells. Because models involving erythroid differentiation of CD34+ cells have limitations in assessing γ-globin reactivation, we focused on human β-globin locus-transgenic (β-YAC) mice. We used a helper-dependent human CD46-targeting adenovirus vector expressing CRISPR/Cas9 (HDAd-HBG-CRISPR) to disrupt a repressor binding region within the γ-globin promoter. We transduced HSPCs from β-YAC/human CD46-transgenic mice ex vivo and subsequently transplanted them into irradiated recipients. Furthermore, we used an in vivo HSPC transduction approach that involves HSPC mobilization and the intravenous injection of HDAd-HBG-CRISPR into β-YAC/CD46-transgenic mice. In both models, we demonstrated efficient target site disruption, resulting in a pronounced switch from human β- to γ-globin expression in red blood cells of adult mice that was maintained after secondary transplantation of HSPCs. In long-term follow-up studies, we did not detect hematological abnormalities, indicating that HBG promoter editing does not negatively affect hematopoiesis. This is the first study that shows successful in vivo HSPC genome editing by CRISPR/Cas9.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Li C, Psatha N, Sova P, et al. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing. Blood. 2018. PMID: 29789357. doi:10.1182/blood-2018-03-838540

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。